|
AstraZeneca PLC on Wednesday said its Tagrisso, used together with chemotherapy, showed improvement in progression-free survival for patients with lung cancer. The Cambridge, England-based pharmaceutical maker said results from the Flaura2 Phase III trial revealed that Tagrisso, or osimertinib, in combination with chemotherapy, demonstrated clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced or metastatic EGFRm non-small cell lung cancer. EGFRm stands for epidermal growth factor receptor mutant. Principal investigator for the trial, Pasi Janne, said: ‘As the global standard of care for EGFR-mutated non-small cell lung cancer, osimertinib monotherapy has transformed the treatment landscape allowing many patients the opportunity to achieve improved survival.’ NSCLC is the most common form of lung cancer. There are an estimated 2.2 million people diagnosed with lung cancer globally each year with 80-85% of patients diagnosed with NSCLC. Tagrisso is approved as monotherapy in countries including in the US, EU, China and Japan. AstraZeneca shares were up 0.6% at 12,142.00 pence early Wednesday in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
